Home Sign In About Curriculum Activity Information Target Audience Learning Objectives Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Novartis Oncology

Created in consultation with
Projects In Knowledge®, developers of certificate programs in medicine.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

Course materials have been developed for use outside of the United States.
banner

  Learning Objectives  |   Posttest  |   Technical Requirements
Series of 10 Reports from the 50th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, California 2008

At the 2008 Annual Meeting of ASH, new data from a number of studies were presented on the benefits of iron chelation, particularly in preventing/reversing myocardial iron overload. These reports discuss the recent clinical trial results, focusing on the impact of different regimens of deferasirox, deferiprone, and desferrioxamine on cardiac iron accumulation in patients with a variety of transfusion-dependent anemias, as well as the efficacy of treatment with iron chelators in reversing/ preventing subclinical hypothyroidism. Iron overload as an independent prognostic factor of survival and the evolution to AML in patients with MDS is also discussed.

Table of Contents
Report 1 Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox
Report 2 Efficacy and Safety of Deferasirox During 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial
Report 3 Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome
Report 4 Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox
Report 5 Comparison of Deferasirox, Deferiprone, and Desferrioxamine Effectiveness on Myocardial Iron Concentrations and Biventricular Function by Quantitative MR in Beta-Thalassemia Major
Report 6 Efficacy and Safety of Deferasirox in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial
Report 7 Efficacy and Safety of Deferasirox in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial
Report 8 Efficacy and Safety of Deferasirox in Patients with Transfusion-Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study
Report 9 Reversal of Hypothyroidism in Well Chelated β-Thalassemia Major Patients
Report 10 Decrease of Mortality during Deferiprone Treatments: Results from A Large Randomised Cohort of Thalassemia Major Patients Under the Auspices of the Italian Society for Thalassemia and Hemoglobinopathie


Target Audience

This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.

Learning Objectives
After participating in this activity, participants should be better able to:
  • Evaluate results from recent clinical trials of deferasirox, deferiprone, and deferrioxamine in order to choose the most effective chelation regimen to reduce/prevent cardiac iron accumulation in your individual patients with transfusion-dependent anemias.
  • Compare dosing schedule and route of administration of available iron chelators in determining treatment that facilitates compliance and increases quality of life of your patients with transfusion-dependent anemias.
  • Apply your knowledge of iron overload as a prognostic factor in survival and evolution to AML in patients with MDS in order to determine when and in whom to institute iron chelation therapy.

top


Posttest

 
ESH-Centre Hayem, Hôspital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France - Contacts
All Rights Reserved - Copyright ESH 2010